Melanoma Patient Shares Experience With mRNA Vaccine Trial
A melanoma survivor speaks at the STAT Summit about the emotional journey of a clinical trial that combined a Merck–Moderna mRNA vaccine with immunotherapy.
16 Oct 2026 0 reads Compiled with AI
#Merck #Moderna #intismeran autogene #Gary Keblish #STAT Summit #Keytruda
Merck and Moderna announced promising results in August from a late‑stage trial of an mRNA cancer vaccine added to immunotherapy. The study suggested a powerful new way to fight tumors, but the data did not reveal what such treatment could mean for a single patient. At the 2026 STAT Summit in Boston, a patient shared his experience. The patient, a public school teacher named Gary Keblish, was diagnosed with melanoma in 2019 and entered the clinical trial for the vaccine intismeran autogene.
Patient’s Trial Journey
Keblish described his diagnosis as a roller‑coaster, feeling shame after missing a dermatologist visit and fearing the future. After two excisions and a referral to a surgical oncologist, he felt hopeful when a referral to an oncologist led him to the trial. He was excited when he was selected for the treatment arm that combined the immunotherapy drug Keytruda with the intismeran vaccine. During the trial, he likened the experience to a ride on "The Magic School Bus", describing the emotional and physical changes.
The trial caused neuropathy that made him less physically active and clouded his judgment, but his family and doctors helped him stay focused. He remained determined to finish the journey. Six years after the tumor was removed, he returned to teaching and is grateful for the treatment. He emphasized the importance of support and staying positive.